.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Continuing Education

Pharmacist Education

Physician Education

Utilizing Oncology Biosimilars to Minimize the Economic Burden Associated With Cancer Treatment: Managed Care Considerations

This activity will review the role of biosimilars in oncology care, with an emphasis on the potential economic benefit. Additionally, payer strategies for the use of biosimilars in clinical practice will be emphasized.

Discussing Clinical and Payer Insights to Encourage the Adoption of Oncology Biosimilars into Practice

Classify the core concepts that drive the biosimilar approval process and identify how it differs from the approval of an originator biologic.

Oncology Biosimilars: The Value to Managed Care

Examine the considerations for incorporating a biosimilar into a managed care formulary

Biosimilars: A Managed Care Update of Real-World Evidence and Cost-Savings Data When Treating Inflammatory Conditions

This activity will identify the patient populations with rheumatic and inflammatory disease and consider the biologic costs associated with pharmacologic treatment.